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Dr ChoncholC
doi:10.1016/j.jtcvs.2007.04.029bjective: End-stage renal disease is an independent predictor of mortality after
oronary artery bypass grafting. Limited information exists, however, regarding the
mpact of chronic kidney disease on long-term outcome after bypass grafting. The
urpose of this study was to assess the impact of kidney function on long-term
utcomes in patients undergoing coronary artery bypass grafting.
ethods: We studied 931 consecutive patients undergoing coronary artery bypass
rafting in a single center. Demographic and clinical data were collected preoper-
tively. Chronic kidney disease was defined preoperatively according to the Mod-
fication of Diet in Renal Disease equation as an estimated glomerular filtration rate
ess than 60 mL · min1 · 1.73 m2. Multivariate Cox proportional hazard analyses
ere performed to determine the independent prognostic factors after bypass graft-
ng. The primary outcome was a composite, combining death, acute coronary
yndrome, stroke or transient ischemic attack, and coronary or peripheral revascu-
arization during follow-up. Secondary outcomes were overall causes of death and
ardiovascular death, acute coronary syndrome, and stroke or transient ischemic
ttack.
esults: One hundred fourteen (12.2%) patients had preoperative chronic kidney
isease (estimated glomerular filtration rate range, 20.5-59.8 mL · min1 · 1.73 m2).
fter a mean follow-up of 3.1  1.4 years (median, 3.3 years), chronic kidney
isease was found to be an independent predictor of the composite outcome (hazard
atio and 95% confidence interval, 1.46 [1.01-2.11]; P  .0467) and overall death
hazard ratio and 95% confidence interval, 1.89 [1.16-3.07]; P  .0106).
onclusions: Beyond the perioperative period, preoperative moderate-to-severe
hronic kidney disease is an independent long-term predictor of cardiovascular
vents and total mortality after coronary artery bypass grafting. Chronic kidney
isease status should be incorporated into prediction models and clinical risk
ssessments.
ith the aging of the population in Western countries, as well as the
dramatic growth of reported rates of hypertension and diabetes, the
prevalence of chronic kidney disease (CKD) and impaired kidney func-
ion is also increasing dramatically.1,2 These two latter conditions are frequen
ssociated with widespread atherosclerotic disease,3 and as a consequence, corona
rtery bypass grafting (CABG) is increasingly considered for patients with definite
KD or kidney dysfunction.4
Several studies have reported a poor outcome in patients with end-stage renal
isease5,6 and kidney dysfunction after CABG,7-9 but long-term data for the lat
ase are scarce. Additionally, most studies that have shown an association between
reoperative kidney disease and a higher incidence of morbidity and mortality after
ABG have concentrated on patients with elevated serum creatinine.6,10-13 How-
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CDver, serum creatinine is not a sensitive marker, because its
oncentration is affected by factors other than glomerular
ltration rate (GFR), such as creatinine generation, secre-
ion, and extrarenal excretion.14 Recent published guide-
ines advise estimating GFR from prediction equations in
atients with cardiovascular disease.15,16
There is limited information on the influence of moderate-
o-severe CKD on the long-term survival of patients under-
oing CABG.17-19 The main objective of this study was
nvestigate the impact of preoperative CKD, defined as an
stimated glomerular filtration rate (eGFR) of less than 60
L · min1 · 1.73 m2 measured by the Modification of
iet in Renal Disease (MDRD) study equation on the long-
erm outcomes of cardiovascular events and total mortality
fter CABG.
aterials and Methods
tudy Population and Measures
he study cohort consisted of 931 consecutive patients who un-
erwent CABG at the Dupuytren University Hospital, Limoges,
rance, between August 1998 and January 2002. All study partic-
pants signed an informed consent form before study entry. All
reoperative and perioperative data, which included cardiovascular
istory and cardiovascular risk factors, were collected in a standard
orm. Patients were considered smokers when they were actively
moking or had stopped within 2 years before the operation.
atients were considered to have diabetes if they had a fasting
lood glucose level at entry of more than 7.8 mmol/L or were
aking oral hypoglycemic agents or insulin, or both. Those who
ad a blood pressure of 160/90 mm Hg or higher measured twice
efore surgery or who were taking antihypertensive drugs for that
urpose were considered to have hypertension. Hypercholesterol-
mia was defined by a fasting blood cholesterol level at entry of
ore than 240 mg/dL or by the need for lipid-lowering agents for
hat purpose. Supraventricular arrhythmia was defined by the pres-
nce of sustained atrial fibrillation or flutter on the preoperative
lectrocardiogram. Peripheral vascular disease (PVD) combined
ny report of clinical peripheral arterial disease (ie, an intermittent
laudication and/or a history of vascular surgery for peripheral
rterial disease) and any report of stroke or transitory ischemic
ttack (TIA) and/or any carotid surgery before enrolment. Patients
Abbreviations and Acronyms
ACS  acute coronary syndrome
CABG  coronary artery bypass grafting
CKD  chronic kidney disease
CI  confidence interval
eGFR  estimated glomerular filtration rate
GFR  glomerular filtration rate
HR  hazard ratio
MDRDModification of Diet in Renal Disease
PVD  peripheral vascular disease
TIA  transient ischemic attackndergoing emergency surgery (coronary angiography to surgery b
84 The Journal of Thoracic and Cardiovascular Surgery ● Septeelay  48 hours) were excluded from the analysis. Patients with
cute coronary syndrome (ACS) operated on beyond 48 hours
nd/or presenting hemodynamic instability were considered in an
nstable cardiac status and were included in the study. Preopera-
ive data included the number of bypasses performed, whether the
evascularization was complete, the requirement of cardiopulmo-
ary bypass or an off-pump surgery, and the performance of any
ombined procedure (ie, concomitant valvular or carotid surgery).
efinition of CKD
reoperative serum creatinine was collected at admission. Serum
reatinine was assessed by the Jaffé rate-balked and compensated
ethod, using a kinetic colorimetric assay on the Roche/Hitachi
odular P analyzer (F. Hoffman-LaRoche Inc Ltd, Basel,
witzerland).
We estimated kidney function using a formula derived by the
DRD study group, as suggested by recent published guide-
ines.14,16 This equation expresses GFR in milliliters per min
er 1.73 m2 body surface area and is calculated as 186  (serum
reatinine1.154)  (age0.203)  1.21 (if black)  0.742 (if
emale), where serum creatinine is measured in milligrams per
eciliter and age is in years. We defined CKD as an eGFR less than
0 mL · min1 · 1.73 m2.14
utcomes
he follow-up period corresponded to the interval from the day of
ABG until March 1, 2004. Follow-up was performed by review-
ng hospital charts, as well as by telephone contacts with patients’
amily physicians. The primary outcome was composite, corre-
ponding to the occurrence of at least one of these events during
he follow-up: death, nonfatal ACS corresponding to any type of
yocardial infarction or unstable angina after surgery requiring
dmission to a coronary care unit, secondary coronary revascular-
zation, nonfatal stroke or TIA requiring admission to a neurology
epartment and defined by a neurologist during the hospital stay,
nd peripheral vascular surgery. Secondary outcomes studied were
verall mortality and cardiovascular mortality.
tatistical Analysis
ll statistical analyses were performed with SAS software version
.2 (SAS Institute, Cary, NC). Summary statistics (mean and
tandard deviation for continuous variables and N and percent for
iscrete variables) were performed for all covariates, first for the
verall sample and then separately by kidney function status.
omparisons were made between the two groups with t tests or 2
ests, as appropriate. Univariate Cox regression models were per-
ormed for each covariate for each primary or secondary outcome.
he CKD status, as well as all other covariates being significant in
nivariate analyses, was entered into a multivariate model. Cox
odels were run successively with backward stepping, at each step
emoving the least significant term. The backward stepping con-
inued until only significant terms remained in the model. Kaplan–
eier survival curves were produced for the composite, overall
auses of death, and cardiovascular death outcome showing the
urvival curves for each CKD group. Nonlinearity between con-
inuously measured eGFR and the outcome measures was explored
y fitting restricted cubic splines, as well as by fitting a third-
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CDegree polynomial model. Log–rank statistics were calculated
omparing the two groups.
esults
aseline Characteristics
n this study population of 931 patients, 114 (12.2%) had
oderate-to-severe CKD as defined above (mean eGFR
6.6  10.7 mL · min1 · 1.73 m2, range: 20.5-59.8
L · min1 · 1.73 m2). These subjects were older, were
ore likely to be female, and were more likely to have a
istory of hypertension, diabetes, PVD, and New York
eart Association class III or IV than participants without
KD. A higher proportion of concomitant valvular surgery
as noted in those with CKD (Table 1).
ollow-up
atients were followed up for a mean of 3.1  1.4 years
median, 3.3 years) after surgery.
During this period, 192 (20.6%) patient results met the
rimary outcome. Ninety-four patients died, including 60
ases of cardiovascular death. Forty-two patients had ACS
uring follow-up, and 28 underwent secondary coronary
evascularization. Thirty-three had a stroke or TIA, and 40
ad peripheral vascular surgery.
Primary outcome. During the entire follow-up period,
7 (32.5%) patients in the CKD group and 155 (19%) in the
roup without CKD met the primary outcome (P  .0009).
ABLE 1. Baseline characteristics in participants by base
haracteristics All (n  931) (mL ·
ge (y) 66.9 9.3
ale gender, n (%) 764 (82.1)
MI  30 kg/m2 (%) 160 (17.2)
moking, n (%) 278 (29.9)
ypercholesterolemia, n (%) 559 (60.2)
ypertension, n (%) 457 (49.1)
iabetes, n (%) 246 (26.5)
upraventricular arrhythmia, n (%) 77 (8.3)
jection fraction (%) 63 14.8
YHA III/IV, n (%) 151 (16.2)
riple vessel disease, n (%) 604 (64.9)
o. of bypasses 3.01 0.98
MCA stenosis  50%, n (%) 151 (16.2)
edo surgery, n (%) 46 (4.9)
nstable cardiac status, n (%) 147 (15.8)
n-pump surgery, n (%) 814 (87.4)
omplete revascularization, n (%) 791 (85%)
oncomitant valvular surgery, n (%) 145 (15.6)
oncomitant carotid surgery, n (%) 27 (2.9)
eripheral vascular disease, n (%) 201 (21.6)
GFR (mL · min1 · 1.73 m2) 75.5 15.4
alues presented with  are means  SD. BMI, Body mass index; eGFR, e
ork Heart Association.
The Journal of Thoracicigures 1, 2, and 3 show the composite, overall, and
iovascular freedom from events curves according to the
bsence or presence of CKD, respectively. In univariate and
ultivariate analyses (Table 2), moderate-to-severe CK
igure 1. Kaplan–Meier estimates of probability of the composite
nd point after CABG by eGFR category. GFR is expressed in
illiliters per minute per 1.73 m2. CKD, Chronic kidney disease;
ABG, coronary artery bypass grafting; eGFR, estimated glomer-
lar filtration rate; GFR, glomerular filtration rate.
kidney function
GFR > 60
1.73 m2) (n  817)
eGFR < 60
(mL · min · 1.73 m2) (n  114) P value
.5 9.0 69.7  10.3 .0023
92 (84.7) 72 (63.2) .0001
33 (16.3) 27 (23.7) .0503
48 (30.4) 30 (26.3) .3774
99 (61.2) 60 (53.1) .0980
79 (46.4) 78 (68.4) .0001
98 (24.3) 48 (42.1) .0001
63 (7.7) 14 (12.3) .0970
.1  14.7 62.2  15.6 .5691
24 (15.2) 27 (23.7) .021
30 (64.9) 74 (64.9) .9932
02 0.98 2.93  0.99 .3426
26 (15.4) 25 (21.9) .0785
41 (5.0) 5 (4.4) .7704
24 (15.2) 23 (20.2) .1722
12 (87.2) 102 (89.5) .4829
96 (85.2) 95 (83.3) .6034
18 (14.4) 27 (27) .0108
23 (2.8) 4 (3.51) .6793
63 (20) 38 (33) .0011
.1 11.3 46.6  10.7 .0001
ted glomerular filtration rate; LMCA, left main coronary artery; NYHA, Newline
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A
CD as independently associated with the occurrence of the
rimary composite outcome during follow-up. The model
as repeated, replacing the binary CKD variable by eGFR
s a continuous variable. After multivariate adjustment,
GFR remained significantly associated with the primary
utcome, with a hazard ratio (HR) at 1.11 (95% confidence
nterval [CI] 1.01, 1.22; P  .0396) per 10 mL · min1 ·
.73 m2 decrease of eGFR (full model not shown). Other
ndependent predictors of the primary outcome included
ncreased age, preoperative supraventricular arrhythmia,
ew York Heart Association class III or IV, concomitant
alvular surgery, presence of PVD, and unstable cardiac
tatus. Furthermore, the relationship between eGFR and
utcome appeared linear, since no additional information
as provided with nonlinear models.
Secondary outcomes. During the follow-up period, par-
icipants with CKD also had higher rates of overall deaths
23.7% vs 8.2%; P  .0001) and cardiovascular deaths
12.3% vs 5.6%; P  .007) than patients without CKD.
KD was also a powerful predictor of overall mortality in
nivariate and multivariate analyses but was only shown to
e a predictor of cardiovascular death in the univariate
nalysis (Table 3). The model was repeated with eGFR 
s a continuous variable instead of CKD. After multivariate
djustment, the HR of overall death increased by 1.20 (95%
I, 1.05, 1.36; P  .0054) per 10 mL · min1 · 1.73 m2
ecrease of eGFR. No significant association was observed
etween eGFR and cardiovascular death in the multivariate
nalysis (data not shown). Other independent predictors for
oth overall and cardiovascular mortality included female
igure 2. Kaplan–Meier estimates of probability of overall sur-
ival after CABG by eGFR category. GFR is expressed in milliliters
er minute per 1.73 m2. Definitions of acronyms as in Figure 1.ender, an ejection fraction less than 40%, unstable cardiac C
86 The Journal of Thoracic and Cardiovascular Surgery ● Septetatus, concomitant valvular surgery, and PVD. In addition,
tting a cubic spline to eGFR revealed a sharp increase in
he composite and overall-death outcome at an eGFR level
f less than 60 mL · min1 · 1.73 m2 (Figure 4).
Postoperative (30-day) outcomes. During the initial post-
perative 30 days of observation, only 28 patients met the
rimary outcome. Twenty-six patients died, 6 had ACS, 4 had
stroke or TIA, and only 1 patient underwent redux coronary
evascularization. In univariate analyses, moderate-to-severe
KD was associated with the occurrence of the composite
utcome (HR  2.42, 95% CI, 1.03–5.69; P  .0431) and
verall death (HR  2.67, 95% CI, 1.22–6.35; P  .0263).
hen eGFR was used as a continuous variable, similar sig-
ificant results were obtained for the composite outcome
HR  1.35, 95% CI, 1.10–1.67) and overall death (HR 
.37, 95% CI, 1.10–1.69). In multivariate analyses, CKD was
ot found to be significantly associated with any of the out-
omes evaluated. In this cohort, the only significant predictors
t 30 days for the composite outcome and overall death in-
luded male gender, New York Heart Association class III or
V, and unstable cardiac status (data not shown).
iscussion
n this longitudinal study, moderate-to-severe preoperative
KD was found to be a significant predictive marker of
ubsequent events in patients after CABG. This prognostic
alue is independent of many usual prognostic comorbidi-
ies, which can be shared between coronary artery disease
nd CKD, including diabetes, hypertension, heart failure, or
he presence of PVD. In this cohort, the 12% prevalence of
igure 3. Kaplan–Meier estimates of probability of cardiovascu-
ar survival after CABG by eGFR category. GFR is expressed in
illiliters per minute per 1.73 m2. Definitions of acronyms as in
igure 1.KD in patients undergoing CABG is relatively low, com-
mber 2007
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A
CDared with 21% to 37% reported elsewhere.9,13,18,19 Never-
heless, CKD was shown to increase the risk for the primary
omposite outcome of death, nonfatal ACS, coronary revas-
ularization, stroke and peripheral vascular surgery, as well
s overall mortality alone, by 46% and 89%, respectively.
Data on moderate-to-severe CKD defined by a more
eliable estimate of kidney function (eGFR) and its prog-
ostic value on a variety of long-term cardiovascular out-
omes are scarce.9,18 In an analysis from The Society 
horacic Surgeons National Cardiac Database, Cooper and
ssociates9 reviewed the case histories of 483,914 patie
eceiving isolated CABG. The authors showed an associa-
ion between eGFR and operative mortality and morbidities,
ut specific long-term cardiovascular end points were not
valuated. In a British study,18 37% of patients undergoin
ABG presented with an eGFR less than 60 mL · min1 ·
.73 m2, and eGFR was an independent predictor of short-
nd long-term mortality. The only outcome evaluated was
verall mortality, and the median length of follow-up was
.3 years. With a longer follow-up period of 3.3 years, our
tudy is the first providing evidence of the additive predic-
ive power of eGFR on a series of combined cardiovascular
nd point and overall mortality.19
Although we did not observe CKD to be an independent
redictor of the short-term (30 days) postoperative outcome,
ost likely because of very few events that had accrued
ABLE 2. Predictors of primary composite end point by Co
haracteristics
Univari
HR (95% CI)
ge 1.04 (1.02–1.06)
ale gender 0.80 (0.56–1.13)
MI  30 kg/m2 1.00 (0.69–1.45)
moking 1.18 (0.88–1.59)
ypercholesterolemia 0.82 (0.62–1.09)
ypertension 1.02 (0.77–1.35)
iabetes 1.06 (0.77–1.46)
upraventricular arrhythmia 2.34 (1.56–3.50)
hronic kidney disease 1.88 (1.31–2.69)
jection fraction  40% 0.58 (0.36–0.94)
YHA III/IV 2.35 (1.70–3.24)
riple vessel disease 0.99 (0.74–1.34)
umber of bypasses 0.97 (0.77–1.21)
MCA stenosis  50% 1.57 (1.10–2.24)
edo surgery 1.05 (0.58–1.88)
nstable cardiac status 1.77 (1.25–2.49)
n-pump surgery 0.90 (0.52–1.57)
omplete revascularization 0.86 (0.59–1.26)
oncomitant valvular surgery 2.29 (1.64–3.19)
oncomitant carotid surgery 1.42 (0.73–2.78)
eripheral vascular disease 1.82 (1.35–2.46)
R, Hazard ratio; CI, confidence interval; BMI, body mass index; NYHA, Nuring this period, the interpretation of the survival curves i
The Journal of Thoracicfter CABG in our cohort suggest that the highest risk of
chieving the composite outcome and overall death in the
roup with CKD can be observed in the initial 12 months
fter surgery. After this period, the survival curves appeared
o be parallel in CKD and no-CKD patients.
The National Kidney Foundation has recommended that
FR should be estimated from prediction equations that
nclude serum creatinine concentration and some or all of
he following variables: age, sex, race, and body size. The
DRD study and Cockcroft–Gault equations provide useful
stimates of GFR in adults.14 We have chosen for o
nalysis to primarily define CKD on the basis of the MDRD
tudy equation because it has been established to be more
ccurate in patients with moderate-to-severe kidney dis-
ase.16 Furthermore, an independent association has be
stablished between reduced eGFR measure by the MDRD
quation and the risk of death, cardiovascular events, and
ospitalization in large, community-based populations.20 In
ddition, the science advisory from the American Heart
ssociation Kidney and Cardiovascular Disease Council
ecently recommended that all patients with cardiovascular
isease should be screened for evidence of kidney disease
ith the combined use of the MDRD equation to estimate
FR and a sensitive test to detect microalbuminuria.15
Studies in patients with cardiovascular disease have con-
istently shown that the level of kidney function is an
gression: Univariate and multivariate analyses
Multivariate
P value HR (95% CI) P value
.0001 1.02 (1.00–1.04) .0455
.2068 — —
.9930 — —
.2720 — —
.1784 — —
.9151 — —
.7186 — —
.0000 1.54 (1.00–2.35) .0480
.0006 1.46 (1.01–2.11) .0467
.0265 — —
.0000 1.55 (1.07–2.25) .0195
.9744 — —
.7556 — —
.0120 — —
.8833 — —
.0011 1.53 (1.08–2.17) .0174
.7054 — —
.4438 — —
.0000 1.69 (1.15–2.47) .0071
.3049 — —
.0001 1.65 (1.21–2.25) .0015
ork Heart Association; LMCA, left main coronary artery.x re
atendependent risk factor for cardiovascular mortality.20-23
and Cardiovascular Surgery ● Volume 134, Number 3 687
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A
CDhis association has multiple explanations: (1) Excess co-
orbidities have been reported in patients with CKD, in-
luding volume expansion resulting from sodium retention,
ypertension, and insulin resistance with impaired glucose
igure 4. Cubic spline analysis for risk of outcome (composite,
eath, and cardiovascular [CV] death) with decreasing eGFR. GFR
s expressed in milliliters per minute per 1.73 m2. eGFR, Estimated
ABLE 3. Predictors of total and cardiovascular mortality
haracteristics
Overall mortality
Univariate M
HR (95% CI) P value HR (95%
ge 1.07 (1.04–1.1) .0000 1.04 (1.01
ale gender 0.48 (0.31–0.75) .0012 0.58 (0.36
MI  30 kg/m2 1.09 (0.65–1.83) .7445 —
moking 1.07 (0.69–1.66) .7496 —
ypercholesterolemia 0.74 (0.49–1.10) .1390 —
ypertension 1.07 (0.71–1.60) .7524 —
iabetes 1.25 (0.80–1.93) .3236 —
upraventricular arrhythmia 2.32 (1.33–4.03) .0029 —
KD 3.04 (1.95–4.81) .0000 1.89 (1.16
F  40% 0.44 (0.24–0.81) .0079 0.46 (0.25
YHA III/IV 2.49 (1.59–3.90) .0001 —
riple vessel disease 0.87 (0.57–1.31) .4972 —
o. of bypasses 0.79 (0.64–0.97) .0262 —
MCA stenosis  50% 1.66 (1.02–2.69) .0424 —
edo surgery 1.18 (0.51–2.70) .6988 —
nstable cardiac status 1.73 (1.06–2.81) .0280 1.80 (1.08
n-pump surgery 2.36 (0.86–6.44) .0951 —
omplete revascularization 0.77 (0.46–1.28) .3105 —
oncomitant valvular surgery 3.19 (2.07–4.93) .0000 2.61 (1.59
oncomitant carotid surgery 1.40 (0.51–3.81) .5114 —
VD 2.02 (1.32–3.09) .0012 1.89 (1.20
R, Hazard ratio; CI, confidence interval; BMI, body mass index; CKD, chron
ew York Heart Association; PVD, peripheral vascular disease.clomerular filtration rate; GFR, glomerular filtration rate.
88 The Journal of Thoracic and Cardiovascular Surgery ● Septeolerance.24 (2) Abnormal vascular biology in CKD 
een widely established; as renal function declines, a host of
bnormalities develops, including increased oxidative
tress, inflammation (eg, increased c-reactive protein),25,26
hosphate retention with medial vascular calcification27
ncreased parathyroid hormone concentrations with myocar-
ial calcification and dysfunction,28 and anemia and le
entricular hypertrophy,29 all of which could increase c-
iovascular disease.23 Increased plasma homocysteine, fi-
rinogen, and uric acid are other cardiovascular risk factors
hat occur with CKD.23,24 (3) Numerous studies23,30 have
inked the presence of CKD with underuse of key cardio-
ascular medications after CABG. (4) Finally, therapeutic
ihilism has been associated with these chronically ill
atients.23
Despite the comprehensive nature of the dataset, there
re several limitations to consider in this analysis. First, we
ere unable to determine the cause and duration of kidney
ysfunction and we did not have information regarding
icroalbuminuria or overt proteinuria. Second, we defined
KD on the basis of eGFR rather than on definite measure-
ents of kidney function; however, direct measurements of
FR are rarely used in clinical practice. Third, hemody-
amic changes that could occur from underlying cardiovas-
ox regression: Univariate and multivariate analyses
Cardiovascular mortality
riate Univariate Multivariate
P value HR (95% CI) P value HR (95% CI) P value
) .0145 1.06 (1.02–1.09) .0017 — —
) .0257 0.44 (0.25–0.76) .0032 0.42 (0.23–0.76) .0041
— 1.14 (0.60–2.15) .6862 — —
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CDotentially affect kidney function were not measured. Fi-
ally, measurements of eGFR were based on a single serum
reatinine determination, which could have been influenced
y unstable cardiac status. The strengths of this study are the
arge number of patients, the inclusion of several demo-
raphic, clinical, and operative factors for the patient, and a
onger follow-up period than that of previous studies with a
imilar eGFR threshold.18,19
In conclusion, the preoperative measurement of kidney
unction, particularly eGFR, is a powerful and independent
redictor of overall mortality and cardiovascular events in
atients undergoing CABG. These results lead us to recom-
end the incorporation of preoperative eGFR into the risk
ssessments of perioperative and long-term outcomes after
ABG.
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